James Elliott, MD
Nephrology · Indianapolis, INNPI 1427218940
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,058 of the $36,982 with a category attached, or 75.9%. 20 manufacturers reported payments, led by AstraZeneca at 40.1% of the total. Reporting peaked in 2024 at $16,044 and has fallen 95.3% since, to $756 in 2025. Among nephrology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $192.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Lilly USA, LLC$7K
- Boehringer Ingelheim$6K
- Bayer$6K
- Amgen$2K
- Otsuka America Pharmaceutical, Inc.$572
- plus $2K from 14 others
What the payments were for
- Consulting fees$4,12011%
- Speaking & faculty fees$28,05876%
- Travel & lodging$2121%
- Food & beverage$4,13411%
- Education$4581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 41 | $14,835 |
| Lilly USA, LLC | 9 | $6,845 |
| Boehringer Ingelheim | 13 | $5,884 |
| Bayer | 27 | $5,547 |
| Amgen(2 entities) | 32 | $1,705 |
| Otsuka America Pharmaceutical, Inc. | 8 | $572 |
| Novartis | 17 | $340 |
| Mallinckrodt Hospital Products Inc. | 7 | $240 |
| Calliditas Therapeutics US Inc. | 10 | $233 |
| Novo Nordisk | 5 | $187 |
| Aurinia Pharma U.S., Inc. | 6 | $128 |
| Travere Therapeutics, Inc. | 5 | $117 |
| Outset Medical Inc | 1 | $101 |
| Apellis Pharmaceuticals, Inc. | 3 | $86 |
| Mallinckrodt Enterprises LLC | 2 | $44 |
| Fresenius USA Marketing, Inc. | 2 | $34 |
| GSK | 1 | $31 |
| Vifor Pharma, Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,982 in reported general payments places this provider in the 90th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 143 | $176,912 |
| XphozahTenapanor Hcl | 27 | $138,663 |
| VelphoroSucroferric Oxyhydroxide | 21 | $118,863 |
| JardianceEmpagliflozin | 65 | $87,906 |
| KerendiaFinerenone | 56 | $82,825 |
| MounjaroTirzepatide | 52 | $63,213 |
| AuryxiaFerric Citrate | 22 | $49,471 |
| OzempicSemaglutide | 16 | $22,246 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $19,723 |
| Potassium Citrate ErPotassium Citrate | 46 | $8,867 |
| Sevelamer Carbonate | 27 | $5,899 |
| Torsemide | 152 | $5,043 |
| Calcitriol | 186 | $4,067 |
| Allopurinol | 170 | $3,601 |
| Febuxostat | 34 | $3,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $14,835 | $196,635163 claims |
| Fresenius USA Marketing, Inc.Velphoro | $34 | $118,86321 claims |
| Boehringer IngelheimJardiance | $5,884 | $87,90665 claims |
| BayerKerendia | $5,547 | $82,82556 claims |
| Lilly USA, LLCMounjaro | $6,845 | $63,21352 claims |
| Novo NordiskOzempic | $187 | $22,24616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 238 nephrology providers in Indiana.
Other nephrology in Indianapolis
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Muhammad MujtabaIndianapolis$71K
- Simit DoshiIndianapolis$63K
- Arjun SinhaIndianapolis$50K
- Brent MillerIndianapolis$46K
- Nupur GuptaIndianapolis$20K
- Judith MaddatuIndianapolis$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.